Lupin Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed a licensing and supply agreement with Zydus Lifesciences to co-market Zydus' innovative Semaglutide Injection (15 mg/3 ml) with a reusable pen device in India. Under the deal, Lupin gets semi-exclusive rights to market the product under the brand names Semanext® and Livarise®, while Zydus retains marketing under SEMAGLYN™, MASHEMA™ and ALTERME™. Lupin will pay Zydus upfront licensing fees and milestone payments, though specific financial terms were not disclosed. The product targets type 2 diabetes and chronic weight management (obesity/overweight), placing Lupin in the high-demand GLP-1 therapy segment.
This deal strengthens Lupin's diabetes and cardio-metabolic portfolio by adding a marquee GLP-1 therapy at a time of surging demand for weight-loss and diabetes drugs in India. The licensing model allows Lupin to participate in this fast-growing segment without bearing full R&D risk, which is likely to be viewed positively by investors.